000			03086nam a22003375i 4500
999			_c399322 _d399322
001			399322
003			ES-MaUEC
005			20240601183307.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			231123s2023 sz | o |||| 0|eng d
020			_a9783031423499
024	7		_a10.1007/978-3-031-42349-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQH588 .S83 _b2023 EB
245	0	0	_aHuman iPSC-derived Disease Models for Drug Discovery _cedited by Markus H Kuehn, Wei Zhu
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aHandbook of Experimental Pharmacology _x1865-0325 _v281
505	0		_aPart 1 General considerations -- Human iPS for clinical applications and cellular products -- 3D-printed iPS disease models -- Part 2 CNS iPSC and organoids -- iPS-derived neurons and brain organoids from patients (brain) -- iPS-derived RGCs (eye) -- iPS-derived glia (brain) -- iPSC to model blood-brain barrier endothelial cells -- Part 3 iPSC-derived nociceptive neurons -- IPSC-based peripheral nerve modeling -- Part 4 Non-neuronal specialized cell types -- iPSC-based drug screening of differentiated cardiomyocyte subtypes -- iPSC-based cardiac disease modeling: from cell to tissue -- iPSC-derived corneal endothelial cell -- iPSC-derived trabecular meshwork (eye) -- iPSC for in vitro disease modeling of diabetes.
520			_aSince their development a decade ago, human induced pluripotent stem cells (iPSC) have revolutionized the study of human disease, given rise to regenerative medicine technologies, and provided exceptional opportunities for pharmacologic research. These cells provide an essentially unlimited supply of cell types that are difficult to obtain from patients, such as neurons or cardiomyocytes, or are difficult to maintain in primary cell culture. iPSC can be obtained from patients afflicted with a particular disease but, in combination with recently developed gene editing techniques, can also be modified to generate disease models. Moreover, the new techniques of 3 Dimensional printing and materials science facilitate the generation of organoids that can mirror organs under disease conditions. These properties make iPSC powerful tools to study how diseases develop and how they may be treated. In addition, iPSC can also be used to treat conditions in which the target cell population has been lost and such regenerative approaches hold great promise for currently untreatable diseases, including cardiac failure or photoreceptor degenerations.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9160528 _aCélulas madre
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-42349-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b06/2024 _dz _eIG _zSI